4D Molecular Therapeutics (FDMT) Accumulated Expenses (2019 - 2026)

4D Molecular Therapeutics (FDMT) has reported Accumulated Expenses for 8 consecutive years, with $6.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 10.38% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (up 10.38% YoY), while the FY2025 annual figure was $13.8 million, down 26.83% from the prior year.
• Accumulated Expenses declined to $6.2 million in Q1 2026 per FDMT's latest filing, from $13.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $24.2 million in Q3 2025 and bottomed at $2.9 million in Q2 2022.
• Historically, Accumulated Expenses has averaged $9.2 million across 5 years, with a median of $6.2 million in 2026.
• Annual changes were most pronounced in 2022 — Accumulated Expenses slumped 40.04% — and 2025, when it jumped 249.29%.
• 4D Molecular Therapeutics' Accumulated Expenses stood at $5.7 million in 2022, then soared by 43.24% to $8.1 million in 2023, then soared by 131.55% to $18.9 million in 2024, then declined by 26.83% to $13.8 million in 2025, then plunged by 54.77% to $6.2 million in 2026.
• Business Quant data shows FDMT's Accumulated Expenses at $6.2 million in Q1 2026, $13.8 million in Q4 2025, and $24.2 million in Q3 2025.